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ReviewIlluminating Autoimmune Regulators
through Controlled Variation
of the Mouse Genome Sequence
Identifying Autoimmune Disease Genes:
A Signal to Noise Ratio Problem
Over the past 15 years, considerable efforts worldwide
have been devoted to mapping the genetic loci associ-
ated with autoimmunity (Kelly et al., 2002; Mohan, 2001;
Carola G. Vinuesa and Christopher C. Goodnow*
John Curtin School of Medical Research and
Australian Phenomics Facility
The Australian National University
Mills Road
Todd and Wicker, 2001). In human population studiesCanberra, ACT 2601
or crosses between different strains of mice, over 50Australia
lupus-susceptibility linkage regions have been found,
but it has proved very difficult to identify the causative
gene variants themselves. Two factors contribute to this
difficulty. First, there appear to be many different lociGene variants in mice that have strong, Mendelian
contributing additively, epistatically, or heterogeneouslyeffects on autoimmune susceptibility have been one
to the autoimmune phenotype, so that individual geno-of the most productive entry points for identifying
type-phenotype correlations represent a weak signal togenes and processes regulating human autoimmunity.
trace. Second, there is a high background of noise in theWith the tools now available to map and identify new
form of natural sequence variation—roughly one basemouse Mendelian gene variants, the handful of spon-
change in every thousand between different humans ortaneous mutations accumulated over several decades
rodent strains—so that every gene in a mapped intervalhave all been identified, and the main bottleneck lies
typically contains multiple sequence variants. In humansin producing new Mendelian immune variants. We out-
with organ-specific autoimmunity, the combination of
line here a strategy to generate large sets of functional
massive population studies, linkage disequilibrium anal-
variants in genes controlling lupus and humoral immu- yses, and biological analysis of plausible candidate
nity, based upon limited variation of the mouse ge- genes has been able to overcome these problems in
nome sequence with the chemical mutagen, ENU, several notable cases (Bennett et al., 1995; Morahan et
combined with a set of sensitive immunological screens. al., 2001; Pugliese et al., 1997; Ueda et al., 2003; Vafiadis
et al., 1997). In mice, a productive solution to this signal
Toward a Rationally Designed Therapy to noise problem has been to phenotype a set of geno-
for Systemic Autoimmunity typically identical replicates through breeding of con-
Global immunosuppression is still the mainstay of ther- genic substrains (Morel and Wakeland, 2000; Rozzo et
apy for most systemic autoimmune diseases. This is al., 2001; Silveira et al., 2001; Todd and Wicker, 2001).
almost always associated with toxicity which can be life Global mRNA profiling of congenic mouse tissues on
threatening and often with lack of efficacy because the microarrays has proved a valuable additional filter to
treatments lack specificity. The search for more specific tease out candidate genes within a congenic interval
therapeutic agents will depend on obtaining a precise (Eaves et al., 2002; Rozzo et al., 2001), although it will
only succeed for gene variants with altered mRNA abun-understanding of pathogenesis (Goodnow, 2001). One
dance.approach to this goal is to identify genetic variants that
Autoimmune regulatory genes and mechanisms thatare consistently associated with disease phenotypes
have so far been identified have almost all come byand define the function of those genes. Already, biologi-
analyzing sequence variants with a stronger genotype-cal agents that target molecules directly involved in dis-
phenotype relationship—primarily spontaneous Mende-ease pathogenesis provide remarkable therapeutic effi-
lian mutations or gene-targeted knockouts (Plotz, 2003;cacy with much less toxicity. A clear example has been
Theofilopoulos and Kono, 1999). For example, sponta-the remarkable effectiveness of TNF-neutralizing agents
neous mouse mutations in Fas (Watanabe-Fukunaga etin rheumatoid arthritis (RA), which is at least as effica-
al., 1992) and FoxP3 (Brunkow et al., 2001) have beencious as standard disease-modifying regimens and is
key entry points for delineating new immunoregulatoryhighly effective at controlling symptoms of arthritis. TNF
processes and guided identification of correspondingantagonists entered clinical trials after identification of
human mutations and definition of specific autoimmune
TNF as a key mediator of synovial inflammation and
syndromes such as ALPS (autoimmune lymphoprolifera-
local bone demineralization in preclinical mouse models tive syndrome) and IPEX (immunodysregulation, polyen-
and clinical samples, reports of polymorphisms in the docrinopathy, and enteropathy, X-linked; Bennett et al.,
TNF gene associated with RA, and studies showing 2001; Chatila et al., 2000). Similarly, human mutations
prompt amelioration of symptoms in mouse models of in complement C4 or C1q (Meyer et al., 1985), AIRE
arthritis following administration of monoclonal antibod- (autoimmune regulator; Nagamine et al., 1997; Finnish-
ies to TNF (Feldmann and Maini, 2001). This success German APECED Consortium, 1997), and NOD2 (Hugot
illustrates the importance of identifying new autoim- et al., 2001; Ogura et al., 2001) have, respectively, re-
mune alleles in order to design more effective, less vealed unexpected pathways for clearance of apoptotic
toxic therapies. cells (Botto and Walport, 2002), thymic deletion to or-
gan-specific antigens (Anderson et al., 2002; Liston et
al., 2003), and regulating immune/inflammatory re-
sponses to cell wall components of gut bacteria (Inohara*Correspondence: chris.goodnow@anu.edu.au
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and Nunez, 2003). Spontaneous mutations in SHP-1 leles that selectively disturb specific protein domains.
As illustrated by point mutant alleles in Zap70, LAT,(Shultz et al., 1993; Tsui et al., 1993), followed by tar-
geted mutations in lyn, CD22, FcgR2, CD5, CTLA4, and Carma-1, and Ikaros (Aguado et al., 2002; Jun et al.,
2003; Papathanasiou et al., 2003; Sakaguchi et al., 2003;PDCD1, have delineated the importance of tuning anti-
gen receptor thresholds via inhibitory feedback signal- Sommers et al., 2002), elimination of an entire protein
can obscure key immunoregulatory functions either be-ing through ITAM-containing receptors and tyrosine
phosphatases (reviewed in Goodnow, 2001; Chambers cause development of the mouse, cell lineage, or cell
response is abolished altogether or because anotheret al., 2001; Greenwald et al., 2002; Okazaki et al., 2002a;
Ravetch and Lanier, 2000). Definition of these genes related protein fills the vacant niche. Here, we review the
background and progress addressing this bottleneckas autoimmune regulators has made them productive
candidates for identifying human autoimmune suscepti- via a complementary strategy: by introducing a limited
number of single base variants into a homogenous non-bility variants (Prokunina et al., 2002; Ueda et al., 2003).
Similarly, targeted knockouts have established the auto- autoimmune mouse strain, coupled with screens to re-
veal variants in autoimmune regulators.immune regulatory and receptor tuning role of the ubi-
quitin ligase, cbl-b (Bachmaier et al., 2000; Chiang et
al., 2000), enabling candidate-based identification of a Controlled Production of Germline Sequence
diabetes-causing mutation in rats (Yokoi et al., 2002). Variants with ENU
Repeated in vivo exposure of spermatogonial stem cells
to the alkylating agent N-ethyl N-nitrosourea (ENU) intro-The Autoimmune Mouse Variant Bottleneck
duces single base pair substitutions throughout theWhile spontaneous or targeted Mendelian autoimmune
mouse genome at a rate estimated between one basemouse variants have been the most productive route to
in every 100,000 and one in two million (Beier, 2000;identifying and understanding autoimmune regulators,
Coghill et al., 2002). More than 80% of ENU-generatedproduction of new variants now represents the chief
germline mutations are either AT to TA transversions orbottleneck to further progress. The human and mouse
AT to GC transitions (Popp et al., 1983). Of the variantsgenomes are currently 95% sequenced, and the coding
that have a phenotypic effect, two-thirds interfere withsequence for greater than 80% of genes is annotated,
gene function by changing a single codon to encode asetting out orthologous human and mouse genes (Oka-
different amino acid, and the rest cause either splicingzaki et al., 2002b; Waterston et al., 2002). This remark-
errors or nonsense (stop) codons (Justice et al., 1999).able set of sequence blueprints, coupled with the power-
These point mutations thus hold the unique attractionful tools for fine-mapping Mendelian mutations in mice,
of altering discrete domains and functions of encodedremoves many previous barriers to identifying autoim-
proteins rather than creating simple null alleles. Basedmune regulators. More than three quarters of mamma-
on the frequency of new loss-of-function alleles mea-lian genes have nevertheless not yet been attributed a
sured at a considerable range of loci, ENU treatment ofbiological function (Nadeau et al., 2001). Moreover, even
male mice yields an average of one new loss-of-functionfor genes that already have well-established roles in
mutation per gene in every 1000 gametes (Hitotsumachilymphocyte activation, such as ZAP-70, LAT, or Carma-1,
et al. 1985; Beier, 2000; Coghill et al., 2002; Justice etspecific-sequence variants at key residues can alter
al., 2000). Thus, if 500 to 1000 gametes were to be testedtheir function in ways that cause hypersensitivity/auto-
by a suitable breeding and immunological screeningimmunity rather than immunodeficiency (Aguado et al.,
strategy, the majority of immunoregulatory genes that2002; Jun et al., 2003; Sakaguchi et al., 2003; Sommers
could be detected by the screen will have been repre-et al., 2002). The handful of spontaneous autoimmune
sented by at least one loss-of-function variant. Onceor immunodeficient mouse mutants accumulated during
each variant has been recognized and successfullythe pregenomic period has already been mapped and
propagated to establish a true-breeding line, with chro-sequence variants identified. Postgenome, the chief gap
mosomally linked molecular markers to identify carriers,now lies at the front end of genetic analysis, in producing
the process of distribution, analysis, fine-mapping, andnew Mendelian mouse variants with autoimmunity or
sequencing each variant is relatively straightforward andaltered immune responsiveness.
represents a tremendous potential resource for the re-Targeted production of new mouse variants, either
search community to link genome with “phenome.” Theby homologous recombination in ES cells or by gene
front-end steps of recognizing immunological variantsknockdown with RNAi, provides only a partial solution
and establishing them as readily distributable strainsto the mutant bottleneck. These gene-driven strategies
nevertheless pose considerable challenges, which wetend to be biased toward a narrow band of candidate
address below.genes of known immunological relevance, and limited
understanding of complex processes such as self-toler-
ance or immune regulation makes identification of new Breeding Strategies to Identify Immune Variants
Most variants in immunoregulatory genes are loss-candidate genes difficult. A further difficulty lies in the
fact that autoimmune-prone knockout mice are usually of-function alleles that have either recessive or semi-
dominant effects on the immune system. To recognizegenerated on a 129/Sv genetic background, a strain with
a confounding intrinsic propensity to develop autoim- them, sequence variants in the ENU-treated gametes
need to be bred to homozygosity through a three-gener-munity and autoantibodies (Santiago-Raber et al., 2001).
Gene knockout or knockdown strategies commonly aim ation breeding program (Nelms and Goodnow, 2001)
(see examples in Figures 2 and 4). The process startsto eliminate whole proteins, as opposed to natural se-
quence variation which most often yields missense al- with individual generation 1 (G1) offspring of ENU-
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treated males. Each G1 mouse is estimated to carry an Immunization Screens
independent set of30 loss-of-function variants on the A battery of immunization tests has been developed
paternal chromosomes, based on the average fre- and validated to identify variants in genes involved in
quency of new loss of function variants per gamete (1/ antibody production. The aim of this screen has been
1000) and the number of mammalian genes (30,000). to develop a resource of new strains that will identify
For immunological variants, two unrelated G1 mice are new processes and immunosuppressive targets to in-
paired together, founding a pedigree with an estimated hibit autoimmune or allergic antibody responses or to
60 functional variants including those on the paternally enhance vaccination and immunity. Preimmune serum
derived X and Y chromosomes. Their G2 offspring have from each G3 mouse in each pedigree is first collected
a 50% chance of being heterozygous carriers for any at 8 weeks of age, and the mice are then immunized
variant present in their G1 parents, and five brother- intraperitoneally with alum-precipitated chicken  glob-
sister pairs of these G2 animals are set up with the aim ulin coupled to the hapten arsonate (ABA-CGG) and heat
of achieving four productive pairs. One quarter of these killed Bordetella pertussis (BP) (Figure 1). The primary
G2 x G2 pairs will share any particular variant present antibody response is measured by ELISA in serum 15
in the pedigree, and one quarter of their G3 offspring days later. The CGG response is dominated by IgG1
(1/16 of all the G3s in a pedigree) will therefore be homo- while the BP response is dominated by IgG2a (Toellner
zygous for this variant gene. By producing “libraries” of et al., 1998), providing an internally controlled test for
100 such pedigrees each year—each pedigree founded the ability to polarize T cell-dependent antibody produc-
with different G1 animals, yielding40 G3 offspring per tion to Th2 versus Th1. Figure 2 illustrates an example of
pedigree and taking at least one year to complete—it a variant picked up by this screen and then successfully
is feasible to test an estimated 4000 loss-of-function established as a true-breeding strain over the next 9
gene variants for immune regulatory roles (68% of the months by several generations of breeding and testing
6000 recessive variants present in the 200 G1 found- with the same immunization protocol. Four weeks after
ers). The Australian government, in conjunction with the the first immunization, the mice are boosted with a sec-
ANU John Curtin School for Medical Research, Monash ond immunization of ABA-CGG and the T-independent
University Institute for Reproduction and Development, type 2 antigen, NP-Ficoll, and the secondary immune
The University of Queensland Institute of Molecular Bio- serum is collected 7 days later and tested by ELISA.
science, and the Garvan Institute, has established an The titers of IgG antibody to ABA and CGG provide two
open-access facility, the Australian Phenomics Facility, separate measures of the capacity to undergo affinity
with infrastructure and database systems to support maturation and humoral memory.
construction and testing of many such libraries in paral- In a collaborative program between the ANU and Ox-
lel (www.apf.edu.au). ford University supported by the Wellcome Trust, a panel
The single biggest problem facing this strategy is the of 34 putative immune variants has been isolated in
fact that identifying mice with variant alleles of autoim- this way from 189 pedigrees in two sequential libraries,
mune regulators is much less straightforward than pick- ENU4 and ENU5, derived from ENU-treated C57BL/6
ing out coat color variants. For this reason, only a handful mice (www.apf.edu.au/resources/wt/). Propagation and
of spontaneous immunological mutants have been col- tracking inheritance of these variants, by immunization
lected in inbred mouse collections over several de- testing of offspring on the parental background and in
cades, in stark contrast to the large collections of visible mapping crosses with other inbred strains, is a key hur-
traits. Large numbers of heritable new variants in auto- dle for establishing true-breeding lines and linked mo-
immune regulators can be recognized by serological lecular markers to facilitate identification of carriers and
and immunization tests, as described below, but these homozygotes by other laboratories. Once each strain
tests are inherently “noisy” with false positives due to has reached this point, it is available for distribution to
nongenetic phenotypic variation. False positives can be
the research community and for expanded analysis of
reduced if one restricts the cutoff defining a putative
genes and immune processes. Development of a broad
mutant (“putant”) to the most extreme variants, but this
information base about immunological phenotypes andcomes at an unacceptable cost of excluding most of
processes in each established strain will be achievedthe heritable variants which have clear but less ex-
by free distribution to the research community on thetreme phenotypes.
condition that all new data obtained about each strainThe pedigree structure described above is designed
be deposited in the Resource database.to provide an alternative solution to this problem, by
allowing familial clusters of heritable variants to be rec-
Screens for Systemic Autoimmune Disordersognized in pedigrees. For example, if one sets a cut-off
Systemic and organ-specific autoimmune diseases arefor interesting variants at the 95% tails of the normal
conducive to genetic dissection by mouse chemical mu-distribution, false positives will occur in 5% of animals,
tagenesis, since the existing mouse autoimmune strainsand the chance of a second false positive in an immedi-
develop remarkably similar autoimmune manifestationsate sibling is still 5%. By contrast, for a heritable reces-
to their human counterparts. Tests for new inheritedsive variant, 25% of siblings are also expected to be
variants in autoimmune regulators should be nonlethal,homozygous for the same variant, so that if ten G3 off-
robust, and highly reproducible with less than 5% falsespring are tested per G2 x G2 pair, it is likely that two
positive rates, and affected animals should preferablyhomozygous variant siblings will be found. This familial
be fertile. Unfortunately, in most complex autoimmuneclustering has proved to be a valuable filter for both the
diseases, such as systemic lupus, overt disease tendsantinuclear antibody and immunization screens de-
scribed below. to have incomplete penetrance as assessed by the
Immunity
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30%–40% lupus concordance in identical (monozygotic)
twins (Kelly et al., 2002). This means that on many occa-
sions the autoimmune phenotypes of new gene variants
will be subtle or incompletely penetrant. A useful strat-
egy is to identify and screen for variants in biomarkers
that are well validated to precede development of overt
disease and thus may be more penetrant than the full-
blown clinical syndrome. This offers the additional ad-
vantage that it allows earlier identification of variant ani-
mals, saving time and increasing the likelihood that
affected animals will breed, although it will also inevita-
bly decrease specificity and raise the number of false
positives. The problem of false positives can be over-
come by the familial clustering strategy outlined above.
Thus, finding clusters of several affected sibling animals
increases the confidence in the heritability of the trait,
before spending considerable effort in several genera-
tions of progeny testing.
Antinuclear antibodies (ANAs) are the most prevalent
biomarker for systemic lupus and represent a sensitive
but relatively nonspecific test for the disease. They are
also found in other systemic autoimmune diseases (i.e.,
scleroderma and mixed connective tissue disorders),
chronic bacterial and viral infections, chronic liver dis-
ease, and a number of malignancies. ANAs can also be
found in 2% of healthy adults and are influenced by age
and sex hormones, with a higher incidence in women
and a further increase in those taking hormonal-based
contraceptives (McMurray, 2003). A higher proportion
of siblings of lupus patients compared to the normal
population develop antinuclear antibodies, suggesting
this serological trait can be more penetrant than devel-
opment of clinical lupus. This conclusion is also borne
out by analyses of congenic mouse substrains isolated
from NZB/W mice (Mohan et al., 1999). ANAs develop
first and may precede clinical manifestations by many
years. Next, antibodies to SS-A and phospholipids oc-
cur. Finally, the more specific lupus-associated antibod-
ies, such as anti-Smith (Sm) and dsDNA antibodies de-
velop close to the onset of clinical symptoms (Arbuckle
et al., 2003).
It follows that detection of antinuclear antibodies may
be a sensitive surrogate assay for detecting an underly-
ing genetic propensity to develop systemic autoimmu-
nity later in life. Detection of ANAs in the serum is simple,
inexpensive, non-invasive, and amenable for implemen-
tation in high-throughput screens of mice. When per-
formed as an immunofluorescence-based assay it is
a robust test for autoimmunity. However, due to their
relatively low specificity for lupus, ANAs found during
Figure 1. Humoral Immunity Screen mouse ENU screens should be analyzed in the context
of stringent criteria such as titer, age of onset (15–20G3 ENU mice are bled at 12 weeks of age, and flow cytometric
analysis of leukocyte subsets, ELISAs for total IgG and IgE, and weeks), pattern of immunofluorescence, and clustering
immunofluorescence for ANAs are performed. Mice are then immu- of at least two affected siblings. In the ANU/Oxford Well-
nized with alum-precipitated ABA-CGG and heat-killed inactivated come Trust program, we have screened a library of 200
B. pertussis. Selective defects in IgG2a against B. pertussis or IgG1
G3 pedigrees of mutagenized C57BL/6 gametes for IgGagainst CGG identify Th1 and Th2 putants, respectively. Five weeks
ANAs by immunofluorescence on Hep-2 cells. Both thelater mice are reimmunized with soluble ABA-CGG and NP-Ficoll.
intensity and pattern of staining were scored, comple-Selective defects in IgM against NP or IgG1 against ABA or CGG
identify TI-2 or memory mutants, respectively. Mice that fail to pro- mented by urinalysis for proteinuria, glycosuria, hematu-
duce an antibody-specific response to both CGG and B. pertussis ria, a FACS-based assay to detect T cell hyperactivation
are reimmunized with keyhole limpet hemocyanin (KLH) to exclude and regulatory T cell numbers, and serum analysis for
the possibility of failed primary immunization. hypergammaglobulinemia (Figure 3). This ANA-based
screen yielded 29 putative autoimmune mouse variants
(www.apf.edu.au/resources/wt/). Some exhibit an ex-
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Figure 2. Putant Identification and Heritabil-
ity Testing
Example of a variant (putant number 6) identi-
fied by the immunization screen as having a
selectively decreased Th1 response (de-
creased IgG2a response to B. pertussis in the
presence of normal IgG1 titers to CGG). The
putant was bred to a carrier sibling and then
established as a true-breeding strain by two
further generations of breeding and testing
with the same immunization protocol.
tended phenotype, such as lymphadenopathy, hemato- strain to be identified by the ANA screen, san roque,
which we have recently taken through fine mapping tological cytopenia, proteinuria, and/or hypergammaglo-
bulinemia. To date, heritability of eight strains has been a 1.5 Mb interval and sequencing each of the 15 tran-
scription units within this interval. The mutation in sanconfirmed, twelve are still in heritability analysis, five
were unable to be propagated, and four were tested roque revealed a novel immunoregulatory gene, well-
conserved across phyla but of previously unknown func-and found not to be heritable. Examples of ANA results
and a family tree for a representative mutant are shown tion (unpublished data). Based on detailed analysis of
homozygous mutants, the gene identified is an essentialin Figure 4.
Validation of this strategy has come from the first negative regulator of T cell activity and cytokine produc-
Figure 3. Systemic Autoimmunity Screen
Summary of the steps to identify and characterize ENU-induced systemic autoimmune phenotypes (see text).
Immunity
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Phenotypic and Functional Subsets of ANA Strains
Intriguingly, the different variant lines develop distinct
nuclear and cytoplasmic autoantibody patterns that
closely mimic those found in patients with systemic au-
toimmune disease (Figure 4). Some lupus manifesta-
tions and autoantibody profiles coincide with sufficient
consistency in different subsets of patients to suggest
that lupus is actually a cluster of related diseases. For
example, Sm and C1q antibodies occur frequently with
renal lupus, RNP antibodies with Raynaud’s phenome-
non and a low incidence of lupus nephritis, SSA antibod-
ies with fetal heart block and extensive dermatitis, and
phospholipid antibodies with thromboembolic disease
and fetal loss. It can be inferred from this that detailed
analysis of lupus serology is an important surrogate
marker of critical pathophysiological events. These find-
ings also suggest that different pathogenic pathways
may contribute to different manifestations, implicating
different genetic abnormalities. For example, C2 defi-
ciency predicts a lupus phenotype characterized by
marked photosensitivity, subacute cutaneous lupus,
and the presence of SS-A antibodies (Meyer et al., 1985).
A positive ANA indicates the presence of autoantibod-
Figure 4. Heritability of ENU-Induced ANA Production and Pat-
ies, but in clinical practice further investigations andterns Identified
clinical findings are required for the diagnosis of sys-Top: Genealogy tree of a pedigree exhibiting a fully penetrant au-
temic autoimmune diseases. Importantly, stratificationtosomal recessive ENU-induced mutation causing ANA production.
of human lupus patients according to discrete clinicalBottom: ANA patterns identified in ENU-mutagenized strains in-
clude: (A) possible mitochondrial, (B) homogeneous nuclear, (C) manifestations such as nephritis, thrombocytopenia,
mixed nuclear and cytoplasm, (D) nuclear envelope, (E) cytoplasmic/ hemolytic anemia, neuropsychiatric disease, and asso-
vimentin, and (F) nuclear speckled. ciated rheumatoid arthritis or presence of anti-dsDNA
has proven the most successful approach in achieving
significant linkages in genome-wide scans. This sug-
tion. This strain provides proof of principle and a tem- gests lupus might comprise a set of different diseases
plate for analyzing the variant genes in each of the new with varying underlying genetic determinants. In clinical
practice, laboratory investigation of patients with possi-ANA autoimmune strains.
ble lupus proceeds from high-sensitivity, low-specificityThe “hit rate” for ANA-positive variants, one in every
tests to more specific investigations. Similarly, once anseventh pedigree, is surprisingly high compared with
ANA-positive strain is identified in the primary screengross abnormalities in blood lymphocyte subsets which
and heritability established, in-depth phenotyping ofoccur approximately once in every ten pedigrees. Never-
ANA-positive strains is necessary to establish a precisetheless, the frequency is consistent with previous work
clinical picture of lupus abnormalities caused by eachrevealing as many as 40 single gene knockouts that can
mutation, enabling direct comparisons with the labora-cause ANAs and lupus-like diseases, involving defects
tory results from different lupus patients and informingin a broad range of cellular processes (Mohan, 2001). B
the human clinical analyses about additional tests thatcells specific for nuclear antigens are part of the normal
may help resolve genetic subsets of lupus (Figure 3).repertoire and dysregulation of numerous pathways in-
For detailed clinical pathology, blood is taken fromcluding T cell and B cell tolerization, activation thresh-
each strain of mice between 10 and 18 weeks of age,olds, and killing or apoptosis of activated lymphocytes,
and the following tests are performed. (1) Full bloodand clearance of DNA or apoptotic cell debris have all
count: Blood is examined on a hematology analyzer (fivebeen shown to lead to antinuclear antibody production
parameter white cell differential) calibrated for analysis
(Mohan, 2001). Furthermore, there is accumulating evi-
of mouse blood. Autoimmune anemia, thrombocyto-
dence that properties that are shared and intrinsic to the penia and leukopenia all occur in lupus as a conse-
autoantigens such as structure, glycosylation patterns, quence of autoantibody production. In strains where
location after cell death, selective cleavage by granzyme cytopenia is identified, serum transfers are performed
B, and certain proinflammatory properties—i.e., intrinsic to determine whether these are antibody mediated. As
chemokine activity of various tRNA synthetases, com- an example, san roque mice have been shown to exhibit
plement fixation ability, or direct TLR9 activation by bac- autoimmune thrombocytopenia since it can be repro-
terial or self-DNA—can play direct roles in enhancing duced in wild-type (WT) littermates upon transfer of se-
autoantibody production (Plotz, 2003). Multiple mole- rum from affected mice. (2) Extended autoantibody anal-
cules in many different pathways are thus likely to play ysis: Additional tests are also performed for antibodies
a role in regulating autoantibody production against sys- that are characteristic of lupus. Serum is screened on
temic self-antigens, and the controlled production of Crithidia luciliae substrate for high-affinity IgG dsDNA
new ANA variants provides a unique resource to investi- antibodies. Tests for IgG antibodies to extractable nu-
clear antigens (SS-A, 52 and 60 kDa antigens, SS-B,gate them.
Review
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Figure 5. Bone Marrow Chimeras Identify
Different Routes to ANA Development
Examples of mixed bone marrow chimeras
constructed using WT donor bone marrow
and/or bone marrow from ANA-producing
ENU strains. All recipients of Anita bone mar-
row develop autoantibodies whereas WT
bone marrow corrects the autoantibody pro-
duction in mixed WT/san roque bone marrow
chimeras. Strikingly, only female recipients of
Anastasia bone marrow develop autoanti-
bodies.
Sm, RMP, Ribosomal P, and Jo-1) are performed by tive. This kind of correction by wild-type blood cells is
typically observed for defects in trans-acting factorsimmunoblot. Already, ANA-positive strains have been
shown to produce antibodies to dsDNA, SS-A, and Ribo- such as Fas-ligand or regulatory T cells. A third pattern
is illustrated by Anastasia, a line that exhibits a strongsomal P antigen. (2) Renal pathology: Evidence is sought
using several approaches. Serum is analyzed for hypoal- female bias in the susceptibility to autoantibodies. Only
the female recipients of anastasia bone marrow developbuminemia and hyperlipidemia (signs of nephrotic syn-
drome). This is combined with testing for proteinuria by ANAs, indicating an interaction between a blood cell
acting gene variant and the recipient’s sex. Strong fe-urinalysis. Significant proteinuria is further characterized
by urine electrophoresis. Finally, kidneys are examined male to male bias (9:1) in ANA production typically oc-
curs in human systemic autoimmune disease and isfor changes of lupus nephritis by light microscopy (he-
matoxylin and eosin, silver staining) and electron mi- thought to be a consequence of the effects of sex hor-
mones on immune regulation, but the absence of ade-croscopy, and immunofluorescence for immunoglobulin
deposition. Three of the strains tested so far have shown quate animal models of lupus showing the typical female
bias has been a significant obstacle in elucidating therenal damage with reabsorption droplets in tubules, am-
yloid-like deposits in the glomeruli, and focal thickening mechanism (McMurray, 2003).
In order to test whether there are T cell- or B cell-of glomerular basement membranes due to immune-
complex deposition and microthrombi in the capillaries. intrinsic proliferation or activation defects, CFSE-
labeled mutant and Ly5 congenic wild-type T cells and(4) Skin pathology: Lupus is characterized by immuno-
globulin deposition at the dermoepidermal junction and B cells are cocultured in the presence of various stimuli
that act through antigen receptors, Toll-like receptors,a lymphocytic infiltrate. Skin is taken at necropsy and
examined by histology for lupus-like infiltrate and by and costimulatory molecules. Expression of activation
markers and proliferation kinetics are assessed by flowimmunofluorescence for lupus band.
The approach used to delineate what cellular and mo- cytometry. This assay provides information about the
requirement for costimulation in mutant cells, a keylecular pathways are altered by each new ANA variant
is summarized in Figure 3. The first step in separating question since known defects that lead to T cell hyperac-
tivation and ANA development abrogate this require-out primary from secondary effects of the variant gene
is to identify whether the defect in each strain resides ment (Bachmaier et al., 2000; Chiang et al., 2000). If
intrinsic T and B cell defects are excluded, the next stepin the hematopoietic system and, if so, whether it is T
and/or B cell intrinsic. This is determined by con- is to look for potential APC-intrinsic defects. These are
initially also studied with mixed bone marrow chimerasstructing radiation chimeras in which RAG-deficient re-
cipients are reconstituted with bone marrow from mu- by looking at macrophage and dendritic cell activation
markers. Finally, if B cell, T cell, and APC-intrinsic de-tant or WT congenic mice, or with a 50:50 mixture of
mutant and WT marrow. The congenic WT donor cells fects are excluded, serum from affected mice is ana-
lyzed for complement or serum amyloid P (SAP) defi-are allotype marked with Ly5a or with Thy1a and IgHa to
enable dissection of panhematopoietic, T and B cell ciencies that can impair the clearance of DNA or
apoptotic cells. In this instance, autoimmune suscepti-defects, respectively. Twelve weeks after reconstitution,
mice are bled and analyzed by flow cytometry and serum bility may reside in nonhematopoietic tissues such as
the liver, and this is tested by reconstituting lethallyantibody testing. FACS experiments are used to deter-
mine whether T or B cell activation is confined to the irradiated mutant recipients with wild-type Ly5a con-
genic bone marrow.mutant-derived cells, indicating a cell-intrinsic defect.
Figure 5 illustrates the functional distinction between
three ANA strains revealed by the mixed bone marrow A Web-Based Public Repository for Data
on Immune Variant Strainschimera approach. In recipients of bone marrow from
the Anita line, ANAs develop when all or only 50% of The data from all ENU-induced ANA-producing mouse
strains identified so far through a Wellcome Trust fundedthe hematopoietic cells carry the variant gene, indicating
that the defect acts cell autonomously in blood cells. program, resulting from the implementation of the immu-
nization and systemic autoimmune screens describedMutations in T and B cell inhibitory molecules such as
Fas or SHP-1 behave in this way. By contrast, in recipi- above is accessible at the following website: www.apf.
edu.au/resources/wt/. The aim is to make the informa-ents of marrow from san roque, mixed wild-type/mutant
bone marrow chimeras do not develop ANAs whereas tion obtained from these strains freely available to the
scientific community and facilitate the transfer of estab-chimeras with 100% mutant blood cells are ANA posi-
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lished mutant mouse strains to interested groups. The animals individually with SSLP markers at the ends of
each chromosome, using the method of Beier (Neuhauswebsite will provide information on heritability, pheno-
typic characterization, and stage of gene identification and Beier, 1998). The linked chromosomal interval is
then confirmed and narrowed by individually typing each(chromosomal linkage, fine mapping, sequencing of
transcripts in interval) for each strain. All recipients of of the initial affected animals with additional SSLP mark-
ers spanning the region of linkage. Once a linked markerthe strains are expected to deposit in the database any
new data on the strains, thus building up an openly has been identified, this greatly facilitates distribution
of strains, since recipient laboratories can use simpleaccessible base of knowledge about immune regulatory
genes and processes. Further development of immuno- PCR tests instead of specialized serological progeny
testing to identify carriers and homozygotes during col-logical screens and screening of new libraries to gener-
ate other variant gene resources is underway in specific ony establishment and experimental analysis.
To reduce the linkage region to 1–2 Mb, subsequentprojects supported by the Juvenile Diabetes Research
Foundation and the Australian NHMRC, and in an ANU- N2 or F2 mice are typed at weaning for two flanking
markers, and useful recombinants within the interval areUCSF collaboration supported by the National Institutes
of Health. kept to localize the point of crossover with additional
SSLPs or SNPs within the interval, for phenotypic analy-
sis once they are 10–18 weeks old and for progenyMapping and Sequencing of Mutations
testing as needed. During this phase, when there mayOnce over the hurdle of identifying a new immune variant
be 100 genes within the linkage interval, mRNAs forand establishing a true-breeding line, the strategy for
any strong candidate genes are fully resequenced. Oncemutation identification involves a well-established ge-
the region has been reduced to 1 Mb or a regionneric process of linkage mapping through intercrosses
containing less than 30 genes, all the mRNAs encodedwith another inbred mouse strain (Jun et al., 2003; Nelms
in the interval are sequenced. By PCR amplification ofand Goodnow, 2001). Choosing the right outcross strain
cDNA in 700 bp overlapping fragments, gel purification,is critical for the identification of mutations that drive
and sequencing, we identify which of these transcriptsautoimmune phenotypes. Initial efforts at mapping lu-
is altered in coding (75% of ENU mutants) or mRNApus-prone strains by outcrossing to the NOD back-
splicing sequences (25% of ENU mutants). In over 40ground proved largely unsuccessful since the NOD
mutant strains arising from the ANU mutagenesis effort,strain has an inherent higher susceptibility to develop
all the mutations have been assigned to one or other ofantinuclear antibodies and a large number of phenocop-
these categories.ies was found when looking for other traits such as
lymphadenopathy and hypergammaglobulinemia. Initial
observations from mapping strategies using CBA/H as Candidate-Based Identification
of Human Lupus Allelesthe mapping partner for ANA strains show some of the
autoimmune phenotypes display decreased clinical and Recent evidence from genome scans has suggested
that the success of identifying disease links to causativeserological severity, which is useful when it prolongs
longevity to the age of screening but can also be prob- gene loci can be enhanced once lupus patients are strat-
ified according to their clinical manifestations (e.g., re-lematic if it suppresses detection of the trait altogether.
In the latter case, another inbred strain such as Balb/c nal, neuropsychiatric, hematological manifestations)
(Martin and Reichlin, 1996; Scofield et al., 2003). If thisor DBA/2 can be used.
Any evidence for dominant inheritance of ANA traits strategy is combined with a powerful and unbiased pro-
gram of candidate gene discovery, where the genotype-is tested in F1 mice, and in this case the mapping cross
proceeds as an N2 outcross of the F1s to CBA. Reces- phenotype association is defined in detail in murine
models, then novel disease pathways are likely tosive mutants are mapped by intercrossing F1 siblings
to yield F2 intercross offspring. Initial linkage to a 10–20 emerge. Once the mutated gene is identified in each
autoimmune-prone strain, the orthologous human genecM (20–60 Mb) chromosomal segment is established by
testing the first 200 N2 or F2 mice for each strain at is automatically identified by reference to the Ensembl
human and mouse genome sequence database. Related10–18 weeks of age for the presence of autoantibodies
and any other specific immune or clinical characteristics genes and protein domains are detected from the data-
base and by well-established p-blast, psi-blast, andidentified in that particular strain. Control crosses are
needed to ensure that suitable cutoffs are used to distin- threading algorithms available on the net. This informa-
tion may point to the cellular subsets and signaling path-guish mutants from other sources of genetic variability
in the cross. ways that may be dysregulated by each mutation and
highlight potential connections between the humanTwo alternative strategies have proved useful for initial
chromosomal linkage assignment of immune variants. genes identified and susceptibility to autoimmune dis-
ease that may have been found in linkage studies. Im-The least labor-intensive method involves pooling equal
amounts of DNA from 15 to 25 mice displaying ANA’s portantly, the Ensembl annotated human genome se-
quence enables immediate design of primers to amplifyor other immune defects. The one pooled sample is then
tested for a high proportion of B6-derived chromosomal the exons of the human candidate lupus genes and
sequence these for variants that may be present in sub-regions by PCR amplification and agarose gel electro-
phoresis of SSLP markers spaced at 20 cM (i.e., 3–4 sets of lupus patients.
Too little is known about the pathogenesis of lupus tomarkers per chromosome). Alternatively, if insufficient
affected animals are obtained in the initial cross, linkage predict whether it will represent a collection of disorders
arising from a range of rare gene variants with strongcan be determined by typing as few as six affected
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and autoimmunity by the molecular adaptor Cbl-b. Nature 403,individual effects (as appears to be the case with NOD2
211–216.truncations in Crohn’s disease) or from complex additive
Beier, D.R. (2000). Sequence-based analysis of mutagenized mice.combinations of common gene variants with weak indi-
Mamm. Genome 11, 594–597.vidual effects. The recent identification of a rare gain-
Bennett, S.T., Lucassen, A.M., Gough, S.C., Powell, E.E., Undlien,of-function variant in CD40 in a subset of lupus patients
D.E., Pritchard, L.E., Merriman, M.E., Kawaguchi, Y., Dronsfield,(Grammer et al., 2004) is consistent with the former.
M.J., Pociot, F., et al. (1995). Susceptibility to human type 1 diabetes
Even if strong variants in the human counterparts of at IDDM2 is determined by tandem repeat variation at the insulin
Mendelian autoimmune-susceptibility mouse alleles gene minisatellite locus. Nat. Genet. 9, 284–292.
only account for a minority of lupus cases, they can still Bennett, C.L., Christie, J., Ramsdell, F., Brunkow, M.E., Ferguson,
have a broad impact. First, these discoveries refine the P.J., Whitesell, L., Kelly, T.E., Saulsbury, F.T., Chance, P.F., and
Ochs, H.D. (2001). The immune dysregulation, polyendocrinopathy,search for additional candidate genes encoding other
enteropathy, X-linked syndrome (IPEX) is caused by mutations ofproteins in the same pathway, such as the other compo-
FOXP3. Nat. Genet. 27, 20–21.nents of the VDJ recombination or IL2R pathways in
Botto, M., and Walport, M.J. (2002). C1q, autoimmunity and apopto-inherited immunodeficiency (Corneo et al., 2001; Notar-
sis. Immunobiology 205, 395–406.angelo et al., 2000), or of the Fas pathway in ALPS (Fisher
Brunkow, M., Jeffery, E.W., Hjerrild, K.A., Paeper, B., Clark, L.B.,et al., 1995; Wang et al., 1999). Second, identification
Yasayko, S.A., Wilkinson, J.E., Galas, D., Ziegler, S.F., and Ramsdell,
of relatively rare disease-associated alleles can have F. (2001). Disruption of a new forkhead/winged-helix protein, scurfin,
significant diagnostic value (e.g., BRCA1 in breast can- results in the fatal lymphoproliferative disorder of the scurfy mouse.
cer [Huttley et al., 2000]). Third, once the pathogenesis Nat. Genet., 68–73.
of severe phenotypes is elucidated in relatively rare pa- Chambers, C.A., Kuhns, M.S., Egen, J.G., and Allison, J.P. (2001).
tients, rational approaches to therapy with much CTLA-4-mediated inhibition in regulation of T cell responses: mech-
anisms and manipulation in tumor immunotherapy. Annu. Rev. Im-broader application may become apparent. This is best
munol. 19, 565–594.illustrated by the development of statin lipid-lowering
Chatila, T.A., Blaeser, F., Ho, N., Lederman, H.M., Voulgaropoulos,therapy for common forms of atherosclerosis, which
C., Helms, C., and Bowcock, A.M. (2000). JM2, encoding a forkwas based upon the recognition of defects in cholesterol
head-related protein, is mutated in X-linked autoimmunity-allergicmetabolism as the cause of premature atherosclerosis disregulation syndrome. J. Clin. Invest. 106, R75–R81.
in rare, early onset patients with homozygous LDL re-
Chiang, Y., Kole, H.K., Brown, K., Naramura, M., Fukuhara, S., Hu,
ceptor defects (Goldstein and Brown, 1990). The R.J., Jang, I.K., Gutkind, J.S., Shevach, E., and Gu, H. (2000). Cbl-b
uniquely high signal-noise ratio for discovering variants regulates the CD28 dependence of T-cell activation. Nature 403,
in autoimmune regulatory genes by controlled variation 216–220.
of the mouse genome sequence with ENU, coupled with Coghill, E.L., Hugill, A., Parkinson, N., Davison, C., Glenister, P.,
Clements, S., Hunter, J., Cox, R.D., and Brown, S.D. (2002). A gene-the syntenic sequences of humans and mice and the
driven approach to the identification of ENU mutants in the mouse.tools for analyzing immune regulatory processes in
Nat. Genet. 30, 255–256.mice, appear to make this a particularly rich strategy
Corneo, B., Moshous, D., Gungor, T., Wulffraat, N., Philippet, P.,for developing specific treatments for lupus and other
Le Deist, F.L., Fischer, A., and de Villartay, J.P. (2001). Identicalimmunological diseases.
mutations in RAG1 or RAG2 genes leading to defective V(D)J recom-
binase activity can cause either T-B-severe combined immune defi-Acknowledgments
ciency or Omenn syndrome. Blood 97, 2772–2776.
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